Cannepil, page-40

Feb 2017: Medical Cannabis Clinical Study Commencing with World Leading Epilepsy Physicians
MGC Pharmaceuticals Ltd (ASX: MXC or “the Company" is pleased to confirm that it is commencing a clinical study following the signing of a binding research agreement with the University Children’s Hospital Ljubljana for a Phase IIA Crossover (non-pivotal) clinical study. The study uses enriched medical cannabis products in children and adolescents with treatment-resistant epilepsy at the Hospital’s Department of Adolescent & Developmental Neurology. The research has also received approval from the Hospital Ethics Committee for the study. Over 65 patients have already been recruited to participate in the 6-week study, with a total of 70 volunteers required to achieve statistical significance. The Company has a large pool of over 150 potential volunteers that have expressed an interest in participating. Under the direction of Dr Neubauer, the Phase IIA Crossover (non-pivotal) study aims to assess the efficacy of MGC Pharmaceuticals' medicinal cannabis formulation, a whole plant extract based medicine with high CBD/THC ratio, and compare it to pure synthetic CBD. The primary end point of the study will be a reduction in the frequency of seizures experienced by individuals suffering from epilepsy.